mbiomics

mbiomics is a provider of a genomic-based platform for microbiome-based therapeutics development, designing and developing complex Live Biotherapeutic Products (LBPs) to change the treatment paradigm of severe and chronic diseases. The company proprietary technology platform covers critical workstreams including large consortia design through data science predicting indication-specific mechanisms of action, a proprietary strain library for translating in silico designs to the laboratory, in-house co-culturing manufacturing processes for over 100 species, precise analytics tracking individual strain viability, and innovative screening platforms for candidate nomination. mbiomics pipeline includes MBX-116, a lead checkpoint-inhibitor co-therapy for advanced melanoma designed to enhance immunotherapy response with first-in-human evaluation, plus programs targeting non-small cell lung cancer, renal cell carcinoma, inflammatory bowel disease, and autism spectrum disorder. The company goal is to access the gut microbiome full immunological and metabolic potential to restore healthy microbial ecosystems. Founded in 2020 and headquartered in Munich, Germany, mbiomics has raised approximately 5.2 million in a Series A round with investors including Bayern Kapital, HTGF, and MIG Fonds.